JP2022511286A5 - - Google Patents

Info

Publication number
JP2022511286A5
JP2022511286A5 JP2021511586A JP2021511586A JP2022511286A5 JP 2022511286 A5 JP2022511286 A5 JP 2022511286A5 JP 2021511586 A JP2021511586 A JP 2021511586A JP 2021511586 A JP2021511586 A JP 2021511586A JP 2022511286 A5 JP2022511286 A5 JP 2022511286A5
Authority
JP
Japan
Prior art keywords
cancer
binding
pharmaceutical composition
domain
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021511586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048913 external-priority patent/WO2020047319A1/en
Publication of JP2022511286A publication Critical patent/JP2022511286A/ja
Publication of JP2022511286A5 publication Critical patent/JP2022511286A5/ja
Ceased legal-status Critical Current

Links

JP2021511586A 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法 Ceased JP2022511286A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862724600P 2018-08-29 2018-08-29
US62/724,600 2018-08-29
US201862734951P 2018-09-21 2018-09-21
US62/734,951 2018-09-21
US201962793235P 2019-01-16 2019-01-16
US62/793,235 2019-01-16
US201962832830P 2019-04-11 2019-04-11
US62/832,830 2019-04-11
US201962890217P 2019-08-22 2019-08-22
US62/890,217 2019-08-22
PCT/US2019/048913 WO2020047319A1 (en) 2018-08-29 2019-08-29 Combination therapies comprising sirp alpha-based chimeric proteins

Publications (2)

Publication Number Publication Date
JP2022511286A JP2022511286A (ja) 2022-01-31
JP2022511286A5 true JP2022511286A5 (cg-RX-API-DMAC7.html) 2022-09-06

Family

ID=69644684

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511588A Pending JP2022512541A (ja) 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法
JP2021511586A Ceased JP2022511286A (ja) 2018-08-29 2019-08-29 Sirpアルファ系キメラタンパク質を含む併用療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021511588A Pending JP2022512541A (ja) 2018-08-29 2019-08-29 Pd-1系キメラタンパク質を含む併用療法

Country Status (9)

Country Link
US (3) US20210379153A1 (cg-RX-API-DMAC7.html)
EP (2) EP3844176A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512541A (cg-RX-API-DMAC7.html)
CN (2) CN112771067A (cg-RX-API-DMAC7.html)
AU (2) AU2019327493A1 (cg-RX-API-DMAC7.html)
CA (2) CA3109354A1 (cg-RX-API-DMAC7.html)
IL (2) IL281095A (cg-RX-API-DMAC7.html)
MX (2) MX2021002292A (cg-RX-API-DMAC7.html)
WO (2) WO2020047328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278865B (zh) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 新的重组融合蛋白及其制备和用途
MX2021002292A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
US20210301019A1 (en) * 2020-03-26 2021-09-30 Aetio Biotherapy, Inc. Bi-specific fusion proteins for depletion of regulatory t cells
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
IL301454A (en) * 2020-09-17 2023-05-01 Shattuck Labs Inc Clinical dosing of SIRP1A chimeric protein
US20230414778A1 (en) * 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
AU2021390545A1 (en) * 2020-12-03 2023-07-06 Shattuck Labs, Inc. Methods of treating cancer using tigit-and light-based chimeric proteins
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
CN117355336A (zh) * 2021-03-05 2024-01-05 沙塔克实验室有限公司 基于SIRP α的嵌合蛋白的联合疗法
JP2024508540A (ja) * 2021-03-05 2024-02-27 シャタック ラボ,インコーポレイテッド SIRPαベースのキメラタンパク質を用いた併用療法
MX2024005649A (es) * 2021-11-12 2024-07-10 Shattuck Labs Inc Proteinas quimericas basadas en sirp1a y cd40l.
CN120923632A (zh) * 2022-05-06 2025-11-11 正大天晴药业集团股份有限公司 靶向cd40和cd47的重组融合蛋白
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
ME03550B (me) * 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
PE20151921A1 (es) * 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
US10046047B2 (en) * 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
SG10201913573UA (en) 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
DK3565579T3 (da) * 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
MX2021002292A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.

Similar Documents

Publication Publication Date Title
JP2022512541A5 (cg-RX-API-DMAC7.html)
JP2024532485A (ja) Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
JP2023509323A5 (cg-RX-API-DMAC7.html)
Weiner et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy
Reichert et al. The future of antibodies as cancer drugs
AU2016276706B2 (en) Combination therapy for the treatment of cancer
JP6039428B2 (ja) 抗her2抗体および組成物
JP7464525B2 (ja) 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質
WO2017017624A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
RS62038B1 (sr) Ciljana tgf beta inhibicija
AU2013255537A1 (en) Humanized pan-her antibody compositions
CN102905723A (zh) 抗fgfr2抗体
EP4190816A1 (en) Anti-cd47 monoclonal antibody and use thereof
CN104093743A (zh) 特异于her3的结合分子及其用途
JP7362614B2 (ja) 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
KR20210132664A (ko) 항pd-l1 항체 및 그의 용도
CN115197325A (zh) 抗体在抗肿瘤治疗中的用途
JP2022512539A5 (cg-RX-API-DMAC7.html)
JP2012025694A (ja) 癌治療剤
TWI887285B (zh) 抗garp抗體與免疫調節劑之組合及其用途
JP2022503621A5 (cg-RX-API-DMAC7.html)
JPWO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
WO2026067461A1 (en) Multispecific antibody protein and uses thereof
HK40081642A (en) Anti-cd47 monoclonal antibody and use thereof